These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26547456)

  • 1. Predicting the Overuse of PCSK-9 Inhibitors.
    Rodriguez-Gutierrez R; Shah ND; Montori VM
    JAMA; 2015 Nov; 314(18):1909-10. PubMed ID: 26547456
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease.
    Paraskevas KI; Mukherjee D; Papas TT
    Curr Vasc Pharmacol; 2024; 22(1):8-10. PubMed ID: 38037835
    [No Abstract]   [Full Text] [Related]  

  • 3. PCSK9 Pleiotropism: In the Same Vein as Statins.
    Park AC; Zhang X; Yeh YS; Razani B
    Circ Res; 2022 Nov; 131(11):890-892. PubMed ID: 36356112
    [No Abstract]   [Full Text] [Related]  

  • 4. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
    Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
    Raal FJ; Giugliano RP; Sabatine MS; Koren MJ; Blom D; Seidah NG; Honarpour N; Lira A; Xue A; Chiruvolu P; Jackson S; Di M; Peach M; Somaratne R; Wasserman SM; Scott R; Stein EA
    J Lipid Res; 2016 Jun; 57(6):1086-96. PubMed ID: 27102113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibitors in the prevention of cardiovascular disease.
    Latimer J; Batty JA; Neely RD; Kunadian V
    J Thromb Thrombolysis; 2016 Oct; 42(3):405-19. PubMed ID: 27095708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
    McDonagh M; Peterson K; Holzhammer B; Fazio S
    J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
    Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
    PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 Inhibitors.
    Natarajan P; Kathiresan S
    Cell; 2016 May; 165(5):1037. PubMed ID: 27203103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications.
    Seidah NG
    Curr Opin Lipidol; 2016 Jun; 27(3):274-81. PubMed ID: 27031271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.
    Cheng JM; Oemrawsingh RM; Garcia-Garcia HM; Boersma E; van Geuns RJ; Serruys PW; Kardys I; Akkerhuis KM
    Atherosclerosis; 2016 May; 248():117-22. PubMed ID: 27015246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amgen's PCSK9 patents upheld.
    Nat Biotechnol; 2016 May; 34(5):452. PubMed ID: 27153262
    [No Abstract]   [Full Text] [Related]  

  • 14. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.
    Helgadottir A; Gretarsdottir S; Thorleifsson G; Hjartarson E; Sigurdsson A; Magnusdottir A; Jonasdottir A; Kristjansson H; Sulem P; Oddsson A; Sveinbjornsson G; Steinthorsdottir V; Rafnar T; Masson G; Jonsdottir I; Olafsson I; Eyjolfsson GI; Sigurdardottir O; Daneshpour MS; Khalili D; Azizi F; Swinkels DW; Kiemeney L; Quyyumi AA; Levey AI; Patel RS; Hayek SS; Gudmundsdottir IJ; Thorgeirsson G; Thorsteinsdottir U; Gudbjartsson DF; Holm H; Stefansson K
    Nat Genet; 2016 Jun; 48(6):634-9. PubMed ID: 27135400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 Association With Lipoprotein(a).
    Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
    Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.
    Ferri N; Ruscica M
    Endocrine; 2016 Dec; 54(3):588-601. PubMed ID: 27038318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
    Navarese EP; Kolodziejczak M; Kereiakes DJ; Tantry US; O'Connor C; Gurbel PA
    Ann Intern Med; 2016 May; 164(9):600-7. PubMed ID: 26999484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Endocrine; 2016 Oct; 54(1):32-37. PubMed ID: 27220940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.